See more : Cvent Holding Corp. (CVT) Income Statement Analysis – Financial Results
Complete financial analysis of CARGO Therapeutics, Inc. Common Stock (CRGX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of CARGO Therapeutics, Inc. Common Stock, a leading company in the Biotechnology industry within the Healthcare sector.
- Majuba Hill Copper Corp. (JUBAF) Income Statement Analysis – Financial Results
- PT Budi Starch & Sweetener Tbk (BUDI.JK) Income Statement Analysis – Financial Results
- BlackRock MuniYield New Jersey Fund, Inc. (MYJ) Income Statement Analysis – Financial Results
- Cognex Corporation (CGNX) Income Statement Analysis – Financial Results
- Chongqing Rural Commercial Bank Co., Ltd. (601077.SS) Income Statement Analysis – Financial Results
CARGO Therapeutics, Inc. Common Stock (CRGX)
About CARGO Therapeutics, Inc. Common Stock
CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.
| Metric | 2023 | 2022 | 2021 |
|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 3.69M | 1.44M | 147.00K |
| Gross Profit | -3.69M | -1.44M | -147.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% |
| Research & Development | 75.79M | 29.37M | 4.46M |
| General & Administrative | 20.92M | 5.40M | 1.52M |
| Selling & Marketing | -3.69M | 0.00 | 0.00 |
| SG&A | 17.23M | 5.40M | 1.52M |
| Other Expenses | 0.00 | -22.00K | 127.00K |
| Operating Expenses | 96.71M | 34.77M | 5.98M |
| Cost & Expenses | 96.71M | 34.77M | 5.98M |
| Interest Income | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.60M | 4.94M | 0.00 |
| Depreciation & Amortization | 3.69M | 1.44M | 147.00K |
| EBITDA | -93.02M | -33.35M | -5.70M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% |
| Operating Income | -96.71M | -34.77M | -5.98M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -1.44M | -6.18M | 127.00K |
| Income Before Tax | -98.15M | -40.95M | -5.85M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 4.92M | 127.00K |
| Net Income | -98.15M | -40.95M | -5.85M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% |
| EPS | -2.38 | -2.13 | -0.30 |
| EPS Diluted | -2.38 | -2.13 | -0.30 |
| Weighted Avg Shares Out | 41.21M | 19.23M | 19.47M |
| Weighted Avg Shares Out (Dil) | 41.21M | 19.23M | 19.47M |
CARGO Therapeutics to Participate in Upcoming Investor Conferences
CARGO Therapeutics Announces ASH 2024 Abstract on CRG-023, a Tri-specific CAR T, Highlighting Innovative Construct Design and Durable Anti-B-Cell Lymphoma Activity
Why Cargo Therapeutics Stock Rocketed Nearly 20% Higher This Week
CARGO Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
CARGO Therapeutics Adds Experienced Biopharma Executive to Board of Directors with the Appointment of Jane Pritchett Henderson as Independent Director
Undiscovered Stocks on the Verge of a Breakout: 3 Names to Know Now
CARGO Therapeutics to Participate in Upcoming Investor Conferences
CARGO Therapeutics Announces $110.0 Million Private Placement Equity Financing
What Makes CARGO Therapeutics, Inc. (CRGX) a New Buy Stock
Wall Street Analysts See a 56.26% Upside in CARGO Therapeutics, Inc. (CRGX): Can the Stock Really Move This High?
Source: https://incomestatements.info
Category: Stock Reports